Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Barratt, Jonathan; Papagianni, Aikaterini; Cournoyer, Serge; NefIgArd Trial Investigators; Maldonado, Rafael; Fu, Ping; Duman, Soner; Novoa, Pablo Antonio; Na, Ki-Ryang; Maes, Bart; Tennankore, Karthik; Rychlik, Ivan; Barron, Maria Belen; Porras, Luis Quintana; Aiello, Joseph; Dionisi, Maria Paula; Arriola, Mariano; Giotto, Ana; Coppock, Gaia; Nitschke, Martin; Cattran, Daniel; Reich, Heather; Sedor, John; Kanigicherla, Durga; Laurin, Louis-Philippe; Bovy, Christophe; Ryan, Jessica; Tesar, Vladimir; Lundberg, Sigrid; Hemmingsson, Peter; Chen, Cheng-Hsu; Campbell, Kirk; Luo, Qun; Liu, Zhangsuo; Safranek, Roman; Cheung, Chee Kay; Luciano, Randy; Hoyos, Ivan Gonzalez; Cartery, Claire; Serre, Jean-Emmanuel; Speeckaert, Marijn; Garcia, Eva Rodriguez; Pai, Pearl; Khwaja, Arif; Trimarchi, Hernán; Baker, Richard; Kristensen, Jens; Wang, Caili; Avasare, Rupali; Paliege, Alexander; Cassini, Evelin; Stylianou, Konstantinos; Robinson, Derrick; Sachmechi, Isaac; Hugo, Christian; Guron, Gregor; Segarra, Alfons; Ergul, Metin; Kurnatowska, Ilona; Stamellou, Eleni; Alamartine, Eric; Rovin, Brad H.; Mohamed, Amr; Kim, Su-Hyun; Esposito, Ciro; Li, Shaomei; Tokgoz, Bulent; Goumenos, Dimitrios; Zhang, Hong; Peh, Chen Au; McCafferty, Kieran; Rehorova, Jitka; Fischbach, Bernard; Kim, Yong-Lim; Kim, Dong Ki; Thakar, Surabhi; Wang, DeGuang; Demoulin, Nathalie; Vrtovsnik, Francois; Yakubtsevich, Ruslan; Chen, Menghua; Kim, Sung Gyun; Fedosiuk, Elena; Ntounousi, Evangelia; Sarav, Menaka; De La Fuente, Jorge; Toussaint, Nigel; Monkowski, Matias; Alvarez, Magdalena; Wei, Jiali; Otte, Britta; Barbour, Sean; Kamal, Fahmeedah; Daroux, Maite; Maxwell, Peter; Cheng, Hong; Stompor, Tomasz; Lu, Wanhong; Francis, Ross; Sandell, Anna; Moriarty, Jim; Linfert, Douglas; Toropilov, Dmitry; Chiurchiu, Carlos; Vaaraniemi, Kati; Ayoub, Isabelle; Maixnerova, Dita; Eren, Necmi; Xiong, Zuying; Losisolo, Patricia; Orias, Marcelo; Vielhauer, Volker; Fellstrom, Bengt; Karl, Alejandra; Lafayette, Richard; Budde, Klemens; Viganò, Sara Maria; Yan, Tiekun; Liu, Bicheng; Wang, Jianqin; Hall, Matthew; Canetta, Pietro; Zermpala, Synodi; Stone, Andrew; Power, Albert; Goicoechea, Marian; Boletis, Ioannis; Hougardy, Jean-Michel; Wadhwani, Shikha; Levidiotis, Vicki; Mulhern, Jeffrey; Mottl, Amy; Fragale, Guillermo; Hruby, Miroslav; Mikhailova, Elena; Hladunewich, Michelle; Lampo, Mauro Guillermo; Ortiz, Fernanda; Flöge, Jürgen; Mark, Patrick; Chen, Lianhua; Chen, Qinkai; Cozzolino, Mario Gennaro; Pamplona, Irene Agraz; Stoppa, Daniela; Lau, Wai Lang; Lv, Jicheng; Masse, Melanie; Luxton, Grant; Xu, Yan; Altiparmak, Mehmet Riza; Ni, Zhaohui; Singh, Harmeet; Gesualdo, Loreto; Makela, Satu; Phoon, Richard; Rizk, Dana; Nowicki, Michal

doi:2157-1716

Information
References (0)
Discussion (0)
Files

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy - RWTH-CONV-250008

Similar records

h1

h2

h3

h4

h5

h6

RWTH

Kontakt

RWTH Publications

Allgemeines